Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-12-16

Clinical Trial Update: Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens [Phase 4]

View source ↗

Summary

Phase 4 trial results update assessing efficacy and safety of rimegepant for the prevention of episodic migraine across multiple dosing regimens.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NURTEC ODT (RIMEGEPANT SULFATE)

Snippet

Sponsor: Pfizer | Conditions: Migraine | Phase 4 | Status: COMPLETED | Results posted: 2025-12-16